Acadia Pharmaceuticals UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right. Good day, everybody. My name is Ash Verma. I cover small-cap biotech and pharma at UBS, and really excited to host ACADIA Pharmaceuticals. Just to give a quick background, ACADIA has DAYBUE and NUPLAZID. I will just pass it on to Catherine, if you can talk a little bit about the story in terms of where the focus of the growth opportunity is in both the products, and then we can talk about the pipeline and other things after that.
Sounds good. We just delivered our quarter results. As a company, we delivered $342 million, which was a 22% year-over-year growth against both the brands that you just talked about. DAYBUE was $140 million, which delivered 39% year-over-year growth. Within that, we also raised our guidance for the year to between $505 million and $520 million. NUPLAZID delivered $202 million, and that was a 12% year-over-year growth, most of that driven by volume. In terms of other highlights that we have shared this quarter, we also had a successful weight-banded dosing approved for our DAYBUE product, which gives us protection out to 2041, which is an additional five years in the U.S., and we are also pursuing that in Europe. We have got $970 million plus on the balance sheet.
Looking forward to also ensuring that we focus that effort on some BD spending.
Great. Awesome. Yeah, thanks for that. I think it is an interesting story. Definitely a lot of growth has come back in a big way, especially, Catherine, since you have been here. So that has been good to see.
Yeah. Especially with the NUPLAZID IP getting extended last year, and then the DAYBUE doing really well.
Yeah, pretty great story, very nicely done. I guess one of the things that people want to see more diversification, obviously, and some of the pipeline programs, it's always there's some inherent risk in these indications, right, when you're looking at it. So when you think about what has happened, either with the negative symptoms of schizophrenia or PWS or now with the ADP, does that change your view in terms of whether you can source the pipeline internally, or do you necessarily need external innovation to come from your BD activities?
Yeah. No, I think we are really excited about our pipeline right now. As you just referred, we just released our RADIANT phase II study, which did what it was intended to do, which was help us design an optimized phase III program that we are designing for regulatory success. So we'll come onto some more specifics around that. We also have the ongoing phase II program in Lewy body dementia psychosis, which we've announced now we'll get the results in Q4 of next year. And a study that we start to get more questions about now, which is ACP-211 in major depressive disorder, and we are looking for phase II results in the second half of next year. So yes, we weren't successful with Prader-Willi syndrome, unfortunately.
But we're super excited about those opportunities that I've just referred to, because we believe together they could offer us real value in terms of peak potential, and along with our ACP-711 product, over $11 billion of peak potential, which is a sizable opportunity for us at ACADIA. But in addition, we are looking to utilize the balance sheet to drive some strategic inorganic growth. And as we've been saying, we're looking in key areas for that, and I'm happy to elaborate a little bit more if that's useful. But we're looking for both, and I think our pipeline in itself offers us some real opportunity, and we're very excited to be investing in that right now.
Great. Awesome. Yeah, I'm looking forward to sort of more fattening of the pipeline here. We'll see more busier pipelines going forward, I guess. Okay, so maybe if I focus on DAYBUE to begin with.
Yeah. Just help us understand, I think in the last one and a half year, definitely things have improved quite a bit.
What are some of the strategies that you've deployed to ramp up that growth?
Right. Yeah. Yeah. Last year, as you may remember, we expanded our field force to allow us to get into the community a little bit more specifically, because 65% of the Rett patients actually are treated by community physicians.
So that's now fully in action. As you know, earlier this year, we launched a new formulation of DAYBUE, which in itself, for life cycle management, doesn't sound that exciting. But for us, we knew it was really important for growth, because we were able to listen to the community, and they asked for a product that was more flexible for their children and something that had a lower volume. This powder for oral solution allows them to sprinkle it into a liquid other than water, and so they can use a flavor that their daughter likes. Also, it's a smaller volume.
The combination of a better flavor profile and a smaller volume is really driving renewed interest, both from naive patients and patients that have previously discontinued. So in terms of the growth opportunity now for DAYBUE within the U.S., that's very exciting. Beyond the U.S., I've been very focused on expanding our global footprint. As you know, we had the DAYBUE approval reversed, the decision reversed, and we got approval in Europe in the last quarter, and we launched in Germany in October. So we now are selling commercial product in Germany. Yesterday, we announced a distribution deal with KYORIN Pharmaceutical, a Japanese pharmaceutical company, to allow us to file in Japan and commercialize in Japan in 2028.
The strategy for driving DAYBUE growth globally is going really well, and I'm looking forward to delivering on even stronger growth as we move into the next few years.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
